Fig. 6: Schematic model for distinct mechanisms explaining organ-specific inhibition of SARS-CoV-2 infection by enzalutamide. | Nature Communications

Fig. 6: Schematic model for distinct mechanisms explaining organ-specific inhibition of SARS-CoV-2 infection by enzalutamide.

From: Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide

Fig. 6: Schematic model for distinct mechanisms explaining organ-specific inhibition of SARS-CoV-2 infection by enzalutamide.

In prostate cells, AR can modulate the expression of TMPRSS2, which serves as an important factor in mediating SARS-CoV-2-driven entry. Thus, an AR inhibitor, enzalutamide can reduce TMPRSS2 expression, subsequently resulting in the attenuated entry driven by SARS-CoV-2. However, distinct from its therapeutic efficacy in prostate cells, enzalutamide fails to prevent SARS-CoV-2 infection due to AR-independent TMPRSS2 expression in lung cells.

Back to article page